NCT05986227View on ClinicalTrials.gov

The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2026

Conditions

Gastroesophageal Adenocarcinoma

Interventions

DRUG

toripalimab FOLFOX

Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT05986227 - The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): | Biotech Hunter | Biotech Hunter